electroCore, Inc. (ECOR)
ECORNASDAQ-CMBiotechnology: Electromedical & Electrotherapeutic Apparatus
$7.26
+0.0800 (+1.11%) today
Regular session, Nov 10, 9:58 AM ET
- Market cap
- $66.98m
- P/E
- –
- EPS, last 4 quarters
- $-1.39
- Dividend yield
- –
- Day range
- $7.09 to $7.52
- 52-week range
- $4.41 to $12.70
- Average volume
- 92.3k
- Previous close
- $7.18
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $16.40, +125.9% from here
Earnings
next estimate $-0.1400Next report
Dec 2025
+2.9%
Mar 2026
0.0%
Jun 2026
+19.5%
Sep 2026
+50.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $8.69m | $9.24m | $9.58m | $9.45m |
| Gross profit | $7.47m | $8.17m | $8.36m | $8.18m |
| Operating income | -$2.88m | -$2.94m | -$5.32m | -$2.77m |
| Net income | -$3.40m | -$3.04m | -$5.27m | -$3.06m |
Last four quarters: revenue $36.97m, margin -40.0%, free cash flow –
News
8 latest- electroCore (ECOR) Upgraded to Buy: Here's What You Should KnowZacks · 23 hours ago
- electroCore (ECOR) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- electroCore Q3 Earnings Call HighlightsMarketBeat · 6 days ago
- electroCore, Inc. (ECOR) Reports Q3 Loss, Misses Revenue EstimatesZacks · 6 days ago
- Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top EstimatesZacks · Nov 2, 2026
- electroCore Targets 2027 EBITDA Profit as VA, Quell and CIPN Opportunities ExpandMarketBeat · Oct 28, 2026
- ElectroCore Files FDA Submission For Quell In Persistent Chemotherapy-Related Neuropathy; Stock Up RTTNews · Oct 28, 2026
- electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar?Zacks · Sep 18, 2026
The company
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company's two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- electrocore.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.